Pharma Sector Check - Can Indian Generic Players Mitigate The Revlimid Cliff? Systematix

Sun Pharma and Cipla better poised to mitigate the Revlimid cliff.

<div class="paragraphs"><p>Various medicines arranged for photograph. (Source: freepik)</p></div>
Various medicines arranged for photograph. (Source: freepik)
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More